Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Triple Negative Breast Neoplasms 12Lung Neoplasms 12Neoplasm Metastasis 11Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Esophageal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Mouth Neoplasms 3Laryngeal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Inflammatory Breast Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2Brenner Tumor 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma 2

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Taxes × 90 days × Clear all
NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
20 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡